Neostigminemethylsulfate , 10mMinDMSO , 51-60-5
Synonym(s):
3-(N,N-Dimethylcarbamoyloxy)-N,N,N,-trimethylanilinium methyl sulfate
CAS NO.：51-60-5
Empirical Formula: C12H19N2O2.CH3O4S
Molecular Weight: 334.39
MDL number: MFCD00011796
EINECS: 200-109-5
| Pack Size | Price | Stock | Quantity |
| 1ml | RMB159.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 175-177 °C(lit.) |
| storage temp. | -20°C |
| solubility | H2O: 1 g/mL |
| form | powder |
| color | white |
| Water Solubility | 1g/10mL |
| Merck | 14,6464 |
| CAS DataBase Reference | 51-60-5(CAS DataBase Reference) |
Description and Uses
Neostigmine is a reversible inhibitor of acetylcholinesterase (AChE; Kd = 260 μM). In a rat model of knee joint inflammation, intrathecal administration of neostigmine (2-30 μg) increases endogenous acetylcholine levels and dose-dependently increases the latency of paw withdrawal in response to thermal and mechanical stimuli (ED50s = 6.6 and 3.5 μg, respectively). Neostigmine (5 μg, i.p.) restores muscle action potentials in mice with a thymopoietin-induced neuromuscular block. Formulations containing neostigmine have been used in the treatment of myasthenia gravis and Ogilvie syndrome.
Cholinergic; miotic; antidote (curare)
Safety
| Symbol(GHS) |   GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H300-H315-H319-H334-H335 |
| Precautionary statements | P261-P284-P301+P330+P331+P310-P304+P340-P305+P351+P338-P342+P311 |
| Hazard Codes | T+ |
| Risk Statements | 28-36/37/38-42/43-26/27/28 |
| Safety Statements | 36-45-36/37/39-28A |
| RIDADR | UN 2811 6.1/PG 2 |
| WGK Germany | 3 |
| RTECS | CY1225000 |
| HazardClass | 6.1(a) |
| PackingGroup | II |
| HS Code | 29242990 |
| Toxicity | LD50 in mice (mg/kg): 0.16 i.v.; 0.42 s.c.; 7.5 orally, (Randall, Lehmann) |
